Human Fms-related Tyrosine Kinase 3 Ligand (hFLT3L)

• 产品编号：CST-8924LC      品牌：CST       原厂货号：8924LC
• 产品分类：蛋白质检测与分析 > 蛋白质，多肽和酶 > 细胞因子和生长因子 > 其它细胞因子和生长因子
• 应用分类：

描述：

CST公司生产的人源重组蛋白FLT3L (hFLT3L) Thr27-Pro185 (Accession #BC126293.1)是从人源293细胞表达而重组的hFLT3L蛋白在末端没有标签，未糖基化的蛋白分子量据推算为18,037Da。DTT-降解蛋白和未降解蛋白由于有糖基化的存在而作为一个24kDa的蛋白而转移。未糖基化的蛋白具有稍高的迁移率与分子内的胱氨酸有关。重组hFLT3L蛋白的N-末端TQDCS的序列通过测序得到。6 μg 还原 (+) 和 非还原的(-) hIL-17A/F通过SDS-PAGE检测，纯度大于98%，所有批次的纯度均高于98%。重组蛋白hFLT3L的生物活性是通过转染了FLT3的BAF3细胞的增殖实验确定的。每个批次的ED50值在1.1 - 2.3 ng/ml之间。内毒素含量：小于0.01 ng /1 μg hFLT3L。

有载体: 每微克hFLT3L蛋白溶解在包含 20 μg BSA的PBS（pH 7.2）溶液中，并通过 0.22 μm 滤膜冻干。

无载体：每微克hFLT3L蛋白溶解在PBS（pH 7.2）溶液中，并通过 0.22 μm 滤膜冻干。

FLT3L 是通过T 细胞和基质纤维原细胞产生(1,2)。FLT3L 的靶标包括多个细胞种类如造血干细胞，B细胞，T细胞，树状细胞和NK细胞(1,2)。FLT3L 与其他的因子结合刺激多能造血细胞的起源并促进NK细胞和树状系列细胞的增殖。FLT3L有两种剪接形式。完整的细胞膜和可溶性的剪接形式都具有生物活性(1)。FLT3L结合到与它同源的酪氨酸激酶的受体FLT3结合激活STAT3和STAT5 (1,3)。FLT3L由于能够通过刺激树状细胞和NK细胞而激发抗肿瘤的能力而得到了研究。

原厂资料：

Source / Purification

Recombinant human FLT3L (hFLT3L) Thr27-Pro185 (Accession #BC126293.1) was expressed in human 293 cells at Cell Signaling Technology.

Molecular Characterization

Recombinant hFLT3L contains no "tags" and the nonglycosylated protein has a calculated MW of 18,037. DTT-reduced and non-reduced protein migrate as 24 kDa polypeptides due to glycosylation, with non-reduced having slightly greater mobility due to intramolecular cystines. The expected amino-terminal TQDCS of recombinant hFLT3L was verified by amino acid sequencing.

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hFLT3L. All lots are greater than 98% pure.

Bioactivity

The bioactivity of recombinant hFLT3L was determined in a cell proliferation assay using BAF3 cells transfected with FLT3. The ED50 of each lot is between 1.1 - 2.3 ng/ml.

Endotoxin

Less than 0.01 ng endotoxin/1 μg hFLT3L.

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hFLT3L. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

Background

FLT3L is produced by T cells and stromal fibroblasts (1,2). FLT3L targets many cell types including hematopoietic stem cells, B cells, T cells, dendritic cells, and NK cells (1,2). FLT3L in combination with other factors stimulates differentiation and proliferation of hematopoietic multipotent progenitors and promotes proliferation of NK cells and dendritic cell subsets. There are two splice variants of FLT3L. Both the integral membrane and soluble splice variants are biologically active (1). Binding of FLT3L to its cognate tyrosine kinase receptor, FLT3, activates STAT3 and STAT5 (1,3). FLT3L is being tested for its ability to stimulate anti-tumor immune response via stimulation of dendritic and NK cells.

注意事项：

Storage: Stable in lyophilized state at 4ºC for 1 year after
receipt. Sterile stock solutions reconstituted with carrier protein
are stable at 4ºC for 2 months and at -20ºC for 6 months. Avoid
repeated freeze-thaw cycles.